(GLOBE NEWSWIRE) — MilanaPharm, a specialty pharmaceutical company focused on the development of innovative, non-opioid pharmaceutical solutions for wound management and pain, announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application entitled “TOPICAL FORMULATIONS AND TREATMENTS”.
The allowed claims cover a method of treating pain in chronic open wounds such as venous leg ulcers, diabetic leg ulcers, abdominal wounds, vasculitic ulcers, abrasions, burns and pressure ulcers in nonmucosal tissue. According to the examiner, the invention provides an unexpectedly superior delivery of the lidocaine over a prolonged period of time, which is not recognized by the prior art. The patent is based on MilanaPharm’s novel drug delivery platform, TRI-726. This proprietary technology is intended to provide sustained release of an active agent, topically, to a target area.
Jim Harwick, President of MilanaPharm, said, “We are pleased that the USPTO has allowed this patent covering our proprietary topical formulation of Lidocaine. With nearly 7 million Americans suffering from painful chronic wounds and a growing opioid crisis, we believe our novel approach to pain management will play a role in improving quality of life and reducing opioid dependence.”
Upon issuance of this new patent, MilanaPharm intends to seek potential commercialization partners within the United States.